...
首页> 外文期刊>Zeitschrift fur Arznei- und Gewurzpflanzen >A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
【24h】

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

机译:一种新的动脉粥样硬化的诊断和治疗方法:脂质体的时代

获取原文
获取原文并翻译 | 示例
           

摘要

The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.
机译:动脉粥样硬化心血管疾病(ASCVD)的后果包括心肌梗死,缺血性卒中和心绞痛,这是全世界死亡率和发病率的主要原因。 尽管目前的治疗策略降低了风险,但患者仍然会遇到ASCVD的后果。 因此,目前的目标是提高早期动脉粥样硬化病变的可视化,以改善残留的ASCVD风险。 在ASCVD的背景下,脂质体的用途可包括用于成像技术的造影剂,以及将抗血栓碱药物,基因和细胞输送到建立的斑块位点。 另外,脂质体具有抗动脉粥样硬化介导的疫苗佐剂的作用。 这里。 我们审查了与脂质体在ASCVD诊断和管理中使用脂质体的科学和临床证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号